London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
30k Sell at 4.822 over on NEX, BUT still taking 75k at 4.822
4.8P Paid again for 6k here.
Same as Fridays close. Three MMs on bid at 4.8, taking 75k at 4.822.
Last five/six buys have been at 4.98
Crumbs, a good link, thanks.
And just to underline the significance of “first patient dosed” It triggered a $3 million dollar milestone payment to Morphosys.
So into the run in now for Xmas, the promise of a New Year and the end I hope to 24/7 reports on Politics.
It has become the norm to me of late to have many sleepness nights, for many different reasons, and on a happy note some tremendous reporting and debate on Sky News reminding us of the three and a half million people living with cancer at an given time in this country, a figure rising year on year by extension of lifes for many people afforded the gift due to better treatments, immunotherapies than there ever have been. It was a great topic as people forget the mental trauma that living with cancer brings to patients , friends and family in the never ending cycle of scans, re diagnosis, ll health and all that comes with that. The problem has dramatically increased simply because people are living longer and a reminder I took from the debates was to recognise it is not all about ""the cure"" for the majority but back to the basics which RG used as his mantra to be able to treat cancer as a chronic condition, a daily battle and always in the minds of those in your life. What I appreciated was the change of focus from cost of treatments to social care for those surviving as given by awesome organisations like McMillans and Cancer Research U.K.
So moving on from that really hoping we get some very good news before year end, and start seeing some bigger volumes on the ask side, as it looks as if the six figure sells are being seen so far less. So less have a great week ans set us up nicely for a clearer run into 2020.
Good posts guys, and Ray couldn"t agree more about both issues you mentioned. One thing that stood out for me in Chris Holloways Presentation was the reiteration that that the MOD1 trial will begin as previously stated, and there was nothing as to how he said it, that did anything but sound that is still the case at this relatively short timeline.
As far as the FDA goes and the resubmission for the IND I have mentioned a few times that I feel some confidence that will happen in the near future, and perhaps the lack of information about further sites is the reult of us getting closer to that occuring. We all know nothing price sensitive comes out from replies from the BOD but it has been a topic i have discussed with CH on a few occasions now, and the non dismissive manner in which he discusses it just makes me feel it is very much alive still.
Crumbs your comments re the share price hit home with me, as I have for so long been averaging down, and my most recent top up 29k at 5.345 was my first for a long time not driven by averaging down, it makes little difference when you get past 240k by buying 8% more, but very simply I felt with an average of just 14p, it was once 41p!! i felt there were numerous avenues for news that will take us back up and past that with a little luck, which I don"t believe we have been spoiled with for far too long.
So tomorrow we have just two full weeks of trading and a day and a half before Xmas and a couple of days before Xmas to get some news out and set us up nicely for a good start to 2020. I think we will do that and rather than just repeat 2020 is a Pivotal Year (like others before it!!!) but I cant think of another time we are so well set up for so many items of inflection based news than there has been before. Onwards forwards guys, and keep punching...................GN
Yes, the potential market is huge.
That is why it is so frustrating that Scancell's science is moving faster than the all important trial data.
I felt this at the beginning of 2018 when CH mapped out the trial timetable and the gap is even bigger now.
Its so important now
a) that the Modi1 trial start date does not slip again
b) Scancell finds a way to open more centres for the SCIB1 trial. I have not written off the FDA finally relenting on whatever objections they have to Trigrid V2 but I don't think we (the Scancell cult) should count on it
d) A complete bonus would be the SCIB2 trial starting in 2020
e) Lastly we have 2 collaborations ongoing that could lead to pre-clinical deals - soon to monetise our assets LOL
This recent article is interesting
Have a look at table 2(b). This show that at the time of writing (Mar 2019) there were very few trials of cancer vaccines in combination with CIs. All the more reason to get these trials started.
' developers of cancer immunotherapies that have yet to reach the market, ranked by total capital raised through a combination of private financing and, where applicable, collaboration revenue and net proceeds from initial public offerings (IPOs)'
'The top 10 startups listed this year have raised a collective $5.596 billion—a sure sign that investors continue to be dazzled by the prospect of rapid, short-term cancer immunotherapy growth.'
' $84 billion cancer immunotherapy market as calculated last year by Reports and Data, which projects that market to more than triple by 2026, to $242.86 billion.'
$242.86 billion realistically prospective market.... yet what is scancells mcap?.... a company with techs that -in theory- could eclipse the limited effectiveness CI likes of keytruda.... yet there is obviously huge market interest here as proven by amounts your BioNTechs etc companies with no commercial therapies can raise and attract seemingly with not much trouble at all.... scancell what? a £3.8 million dilutive 5p a share raising from Vulpes ... something is wrong and hopefully, Vulpes themselves can now correct that
Tops Gen's top 10 Immuno onco 2019 start ups list:
'GEN’s list of the Top 10 Immuno-Oncology Startups, which includes developers of cancer immunotherapies that have yet to reach the market, ranked by total capital raised through a combination of private financing and, where applicable, collaboration revenue and net proceeds from initial public offerings (IPOs). Companies are listed by name, headquarters city, web address, and total capital raised, followed by a brief description of how the capital was raised and a summary of recent news.
The top 10 startups listed this year have raised a collective $5.596 billion, 18.5% above the $4.722 billion garnered by the mostly same 10 companies ranked in last year’s GEN A-List—a sure sign that investors continue to be dazzled by the prospect of rapid, short-term cancer immunotherapy growth.'
Worth a read : https://www.genengnews.com/a-lists/top-10-immuno-oncology-startups-of-2019/
Also from that article a stunning snippet:
'Keytruda thus accounted for nearly 10% of the total $84 billion cancer immunotherapy market as calculated last year by Reports and Data, which projects that market to more than triple by 2026, to $242.86 billion. That’s the highest of three recent estimates for the cancer immunotherapy market in 2026. At the low end, Kenneth Research projected $86.679 billion, while Grand View Research has forecasted $126.9 billion.'
Scancell of course top the list of most overlooked potential Immuno onco game-changers ever for yet another year :)
Very Interesting. I wonder how Brickbio and Scancell came up with similar colour combinations for their logos (blue/orange). Coincidence or something else?
My maths approach does little for shareholder worth. If you have time for shape theory:
Bringing in Bioluminescence helps as well.
Nom, agree with C7, anything on the topic of oncology is very much on topic.
Very interesting for me, a colleague’s husband is currently being treated for advanced multiple myeloma. Thanks for posting.
Nomlungu, that article is not off topic at all. All forms of cancer treatments, immunotherapies have been discussed here and followed in detail over the years, and enormous strides forward are and have been taking place in blood cancers for some time.
There is an enormous new hospital opening early 2020 opposite the existing UCLH sites, in addition to the latest cancer treatments available. This new hospital is dedicated to immunotherapies and rare blood conditions, some not so rare, making it the largest such hospital of its type in Europe I believe.
If this topic interests you well worth reading this and many other links to the subject, as immunotherapies take a larger slice of the market year on year and has been involved already in some of the largest buyouts the industry has ever seen.
Chelseas bus is still in Liverpool, the tyres got nicked!!! GN
Yes, but there's always the next match.
Sean Dyche left early on the team bus leaving the players in the dressing room.
Our football teams today Ray?? lol
Genexine got their Keytruda free by collaborating with Merck.
However, the financial terms of this agreement have not been made public.
"Under the terms of the agreement between Genexine and MSD, through a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Genexine will conduct a Phase 1b/2a clinical trial to access safety and efficacy of the combination therapy, and MSD will provide clinical supplies of Keytruda and offer support to the study. The agreement also includes provision for potential expansion to include Phase III registration studies in the same indication. Additional details were not disclosed."
Scancell may have been able to foster a special deal for Keytruda with Nottingham NHS due to their joint relationships with Notts University. Trying to get other cash strapped NHS authorities to stump up for Keytruda may be to big an ask. This is where big pharma with their deep pockets win over small independent biotects every time.
I would think they are trying their level best to open up some more uk sites but considering the current political situation in might be the wrong time. We can but hope.
We need the FDA to pull their finger out....
O/T but of interest
'Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note.'
There was another reason why I didn"t mention it, I believe you posted there was nothing new except for that mention of sites. TBH I heard it twice and didn"t catch the part where he mentioned it.
Do you feel it will mean no more future U.K. sites, it hadn"t crossed my mind, but should it does it really matter? Especially if we can open the sites in the U,S,A
Morning All, and Botski in reply to your post I just avoided adding any more speculation to the SCIB1 Trial, by way of sites, whilst there is so much unknown to us, not at least how we are overcoming any problems that exist.
It is still my hope that we will be able to submit another IND to the FDA, and when/if granted be able to utilise in Keith Flaherty in whatever capacity we can. Are there enough/if any countries able to burden the cost of Keytruda for the trial?? Again it would all be speculation and TBH not sure why it would mean an end to any other UK trial centres. As you know it has been four months or so since we initiated the trial, it will be good just to know of our plans, progress and a Plan B.
Just my observation and views on the last few posts....
For me, the pertinent phrases are “timelines” and “jam tomorrow”.
The dominant issue with this investment and this potentially life saving treatment is TIME or more accurately, the passage of time. In the short term, this gets us to “tomorrow”. Whether or not this brings the long awaited “jam” remains to be seen.
Either way, time will reveal all. In time we will know how effective the treatments are and, if successful, how much in pounds and pennies each of the shares we currently hold are worth.
Time is what is needed and cannot be skipped or accelerated. But as they say, time is money. Each delay will have a financial impact. So our expected £1 or whatever will be £1 minus value of time delay. A simple concept but an inescapable one.
Nobody talking about trial centres outside UK and US...is that because people dont expect them to materialize...or because people dont want to draw attention to the fact it may well mean no additional UK trial centres.
I would agree with that Knowlesi in large, I just felt it was good to get simple reminders of what we have in our pipelines, and with news pretty scarce, any cureent news of where we are is welcome.
Moving away from what was said, because there was no new news, I just felt CH has gained so much since he was appointed. Encouraging IMHO that in November 2019, it would seem we are still on target to get MOD1 and SCIB2 into clinical trials. Obviously like everybody waiting to here what we are doing with patient recruitment for the SCIB1 Combo Trial, and just personally looking forward to a good build up for news on MOD1.
Funny enough I didn"t see it as jam tomorrow, there was nothing new stated, but likewise there was nothing negative either, just a good reminder of where we are, where we hope to be and when. I am sure around all that with the TCR, Glycans and Mabs we can look forward to quite a few items of positive newsflow. There are 148 views now on that presentation and I wouldn"t mind betting more than a few of us were reminded or picked up on somethimg we hadn"t previously. ATB
Unchanged on the week 4.8/5, and dare I say sellers drying up, just the 165k on Monday and 2 x 50k Tuesday/
Have a good weekend all.
Strange how we can watch the same thing and come away with different opinions - I guess it's conviction bias in action. I came away pretty underwhelmed with CH's presentation to be honest (though I am more inclined to see negatives over positives here) - as always jam tomorrow with these presentations. I would be over the moon If in 15 months they can have the scib1 combo, scib2/CRUK and modi 1 trails in flight. Let's see - now more than ever the bod have to deliver to timelines. Share price is sub 5p for a reason and timelines need to hit. It's been a pretty poor year for scancell imo let's hope 2020 starts to bring some commerical success. Even a Nottingham/Oxford council grant would be welcomed, well it would be a start. Any deal, literally any deal would be hugely welcomed and get the momentum going.